Evidence map›Paper›PMID 29191842›Full record

ArticleHaematologica2018

Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms.

Jon Celay, Teresa Lozano, Axel R Concepcion, Elena Beltrán, Francesc Rudilla, María José García-Barchino, Eloy F Robles, Obdulia Rabal, Irene de Miguel, Carlos Panizo and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The therapeutic importance of acid-base balance.Biochemical pharmacology · 2021
    Review
  5. The Golgi as a "Proton Sink" in Cancer.Frontiers in cell and developmental biology · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Jon CelayDivision of Hematological-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, CIBERONC, IDISNA, Pamplona, Spain.
Teresa LozanoProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
Axel R ConcepcionDivision of Hepatology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
Elena BeltránDivision of Hematological-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, CIBERONC, IDISNA, Pamplona, Spain.
Francesc RudillaProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
María José García-BarchinoDivision of Hematological-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, CIBERONC, IDISNA, Pamplona, Spain.
Eloy F RoblesDivision of Hematological-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, CIBERONC, IDISNA, Pamplona, Spain.
Obdulia RabalSmall Molecule Discovery Platform and Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
Irene de MiguelSmall Molecule Discovery Platform and Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
Carlos PanizoDepartment of Hematology, Clinica Universidad de Navarra, Pamplona, Spain.
Noelia CasaresProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
Julen OyarzabalSmall Molecule Discovery Platform and Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
Jesús PrietoProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
Juan F MedinaDivision of Hepatology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
Juan José LasarteProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain jamcliment@unav.es jlasarte@unav.es.
José Ángel Martínez-ClimentDivision of Hematological-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, CIBERONC, IDISNA, Pamplona, Spain jamcliment@unav.es jlasarte@unav.es.
Universidad de Navarra · ESCentro de Investigación Biomédica en Red de Cáncer · ESClinica Universidad de Navarra · ESNew York University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulatory T (Treg) cells can weaken antitumor immune responses, and inhibition of their function appears to be a promising therapeutic approach in cancer patients. Mice with targeted deletion of the gene encoding the Cl

Indexed as

AnimalsAnionsAntineoplastic AgentsApoptosisCell Line, TumorCell SurvivalChloride-Bicarbonate AntiportersDisease Models, AnimalHumansLeukemia, B-CellLymphoma, B-CellMiceMice, KnockoutPeptidesT-Lymphocytes, RegulatoryXenograft Model Antitumor AssaysAnionsAntineoplastic AgentsChloride-Bicarbonate AntiportersPeptides

Identifiers

PMID29191842
PMCPMC6058773
OpenAlexW2774764821

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.